<DOC>
	<DOCNO>NCT00020644</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness gemcitabine give continuous infusion treat patient advanced metastatic cancer .</brief_summary>
	<brief_title>Continuous Infusion Gemcitabine Treating Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose continuous infusion gemcitabine patient metastatic malignancy . - Determine toxicity profile drug patient . OUTLINE : This dose-escalation study . Patients dose level 1-5 receive gemcitabine IV continuously 72 hour week 1 . Patients dose level 6 7 receive gemcitabine IV continuously 72 hour week 1-3 . Courses repeat every 2 week ( patient dose level 1-5 ) every 4 week ( patient dose level 6 7 ) absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance metastatic malignancy curative therapy exist PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Pulmonary : Corrected DLCO least 60 % expect Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Prior shortinfusion gemcitabine allow Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>